Accepted author manuscript, 546 KB, PDF document
Final published version, 1.04 MB, PDF document
Available under license: CC BY-NC-SA: Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease
AU - Li, Lin
AU - Liu, Ke
AU - Holscher, Christian
AU - Li, Guanglai
AU - Liu, Yue-Ze
PY - 2016
Y1 - 2016
N2 - The growth factor glucagon-like peptide-1 (GLP-1) is neuroprotective in several animal models of neurodegeneration. Here, we analyzed the neuroprotective effects of a novel protease-resistant GLP-1 analogue, (Val 8 )GLP-1-Glu-PAL, which has advantages over older analogues, such as improvement of hippocampal neurogenesis, glucose homeostasis, and insulin secretion. We established an in vitro model of Parkinson's disease using the mitochondrial stressor rotenone in primary cultured mouse neurons pretreated with (Val 8 )GLP-1-Glu-PAL. (Val 8 )GLP-1-Glu-PAL alone did not affect neuronal viability, but prevented the rotenone-induced reduction in cell viability in a dose-dependent manner. In addition, (Val 8 )GLP-1-Glu-PAL pretreatment prevented rotenone-induced proapoptotic changes manifesting as downregulation of procaspase-3 and Bcl-2 and upregulation of cleaved caspase-3. These results demonstrate that the novel agent (Val 8 )GLP-1-Glu-PAL shows promise as a drug treatment for Parkinson's disease.
AB - The growth factor glucagon-like peptide-1 (GLP-1) is neuroprotective in several animal models of neurodegeneration. Here, we analyzed the neuroprotective effects of a novel protease-resistant GLP-1 analogue, (Val 8 )GLP-1-Glu-PAL, which has advantages over older analogues, such as improvement of hippocampal neurogenesis, glucose homeostasis, and insulin secretion. We established an in vitro model of Parkinson's disease using the mitochondrial stressor rotenone in primary cultured mouse neurons pretreated with (Val 8 )GLP-1-Glu-PAL. (Val 8 )GLP-1-Glu-PAL alone did not affect neuronal viability, but prevented the rotenone-induced reduction in cell viability in a dose-dependent manner. In addition, (Val 8 )GLP-1-Glu-PAL pretreatment prevented rotenone-induced proapoptotic changes manifesting as downregulation of procaspase-3 and Bcl-2 and upregulation of cleaved caspase-3. These results demonstrate that the novel agent (Val 8 )GLP-1-Glu-PAL shows promise as a drug treatment for Parkinson's disease.
U2 - 10.4103/1673-5374.177742
DO - 10.4103/1673-5374.177742
M3 - Journal article
VL - 11
SP - 326
EP - 331
JO - Neural Regeneration Research
JF - Neural Regeneration Research
SN - 1673-5374
IS - 2
ER -